NASDAQ: NEUP
Neuphoria Therapeutics Inc Stock Ownership - Who owns Neuphoria Therapeutics?

Insider buying vs selling

Have Neuphoria Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Lynx1 Capital Management LP10% Owner2025-10-21639,110$5.14
$3.28MBuy

1 of 1

NEUP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when NEUP insiders and whales buy or sell their stock.

NEUP Shareholders

What type of owners hold Neuphoria Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Spyros Papapetropoulos111.30%5,999,940$31.62MInsider
Lynx1 Capital Management LP16.24%875,228$4.61MInstitution
Peter Miles Winston Davies5.01%269,984$1.42MInsider
David Ian Wilson4.67%251,939$1.33MInsider
Lynx1 Capital Management LP4.38%236,218$1.24MInsider
Shay Capital LLC3.14%169,059$890.94kInstitution
Advisorshares Investments LLC2.49%134,194$707.20kInstitution
Alan Fisher1.85%100,000$527.00kInsider
Diadema Partners LP0.93%50,000$263.50kInstitution
Ikarian Capital LLC0.88%47,443$250.02kInstitution

1 of 3

NEUP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
NEUP17.61%82.39%Net Buying
NNVC5.60%94.40%
LSTA0.81%99.19%Net Selling
TVGN3.05%96.95%Net SellingNet Selling
CELU2.23%97.77%Net SellingNet Selling

Neuphoria Therapeutics Stock Ownership FAQ

Who owns Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ: NEUP) is owned by 27.19% institutional shareholders, 127.22% Neuphoria Therapeutics insiders, and 0.00% retail investors. Spyros Papapetropoulos is the largest individual Neuphoria Therapeutics shareholder, owning 6.00M shares representing 111.30% of the company. Spyros Papapetropoulos's Neuphoria Therapeutics shares are currently valued at $31.32M.

If you're new to stock investing, here's how to buy Neuphoria Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.